全文获取类型
收费全文 | 21281篇 |
免费 | 1039篇 |
国内免费 | 102篇 |
专业分类
耳鼻咽喉 | 173篇 |
儿科学 | 285篇 |
妇产科学 | 360篇 |
基础医学 | 2795篇 |
口腔科学 | 532篇 |
临床医学 | 1353篇 |
内科学 | 5337篇 |
皮肤病学 | 323篇 |
神经病学 | 1765篇 |
特种医学 | 840篇 |
外科学 | 3570篇 |
综合类 | 91篇 |
一般理论 | 1篇 |
预防医学 | 602篇 |
眼科学 | 538篇 |
药学 | 1615篇 |
中国医学 | 68篇 |
肿瘤学 | 2174篇 |
出版年
2023年 | 110篇 |
2022年 | 208篇 |
2021年 | 333篇 |
2020年 | 266篇 |
2019年 | 308篇 |
2018年 | 384篇 |
2017年 | 285篇 |
2016年 | 376篇 |
2015年 | 400篇 |
2014年 | 516篇 |
2013年 | 636篇 |
2012年 | 998篇 |
2011年 | 1067篇 |
2010年 | 610篇 |
2009年 | 509篇 |
2008年 | 924篇 |
2007年 | 954篇 |
2006年 | 879篇 |
2005年 | 917篇 |
2004年 | 988篇 |
2003年 | 881篇 |
2002年 | 910篇 |
2001年 | 812篇 |
2000年 | 841篇 |
1999年 | 767篇 |
1998年 | 278篇 |
1997年 | 210篇 |
1996年 | 171篇 |
1995年 | 160篇 |
1994年 | 158篇 |
1993年 | 133篇 |
1992年 | 540篇 |
1991年 | 458篇 |
1990年 | 465篇 |
1989年 | 469篇 |
1988年 | 416篇 |
1987年 | 354篇 |
1986年 | 352篇 |
1985年 | 350篇 |
1984年 | 242篇 |
1983年 | 181篇 |
1979年 | 167篇 |
1978年 | 120篇 |
1977年 | 115篇 |
1974年 | 88篇 |
1972年 | 89篇 |
1971年 | 95篇 |
1970年 | 83篇 |
1968年 | 94篇 |
1967年 | 90篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Akiko Horiuchi Norihiko Kikuchi Ryosuke Osada Cuiju Wang Akiko Hayashi Toshio Nikaido Ikuo Konishi 《Cancer science》2008,99(12):2532-2539
Small guanosine triphosphatase RhoA has been known to re‐organize cytoskeletons and regulate cell migration. The present authors have previously reported that expression of RhoA is significantly increased in advanced ovarian carcinomas and also in the peritoneal disseminated lesions. The present study investigated whether overexpression of RhoA could alter the progressive behavior of ovarian cancer cells. The effect of various Rho inhibitors on the biological behavior of ovarian cancer cells in vitro and in vivo was also examined. A stable RhoA‐transfectant of an ovarian cancer cell line SKOV3 was generated and examined in vitro for alterations of proliferative activity and invasiveness, and also in the nude mice model for peritoneal dissemination. In addition, the effect of a specific Rho inhibitor (C3 exoenzyme), Rho kinase inhibitor (Y27632) and hydroxymethylglutaryl coenzyme A (HMG–CoA) reductase inhibitor (Lovastatin and Pravastatin) were studied in vitro and in vivo. Forced overexpression of RhoA did not alter proliferative activity but significantly increased the invasiveness in vitro, which was suppressed by addition of C3 exoenzyme, Y27834, Lovastatin and Pravastatin. In the nude mice model, the frequency of dissemination and the number of disseminated lesions were significantly increased in the RhoA transfectant than in the control. In addition, oral administration of Lovastatin significantly decreased the number of metastatic sites compared with the control. These findings suggest that upregulation and/or activation of RhoA play an important role in the peritoneal dissemination of ovarian carcinoma, and that Lovastatin might be a candidate for the possible, novel treatment for ovarian carcinoma patients with peritoneal dissemination. (Cancer Sci 2008; 99: 2532–2539) 相似文献
992.
Yu Imamura Yoshifumi Baba Shinji Ishikawa Yukiharu Hiyoshi Youhei Nagai Tadahiko Nakamura Naoko Hayashi Nobutomo Miyanari Kenichi Iyama Hideo Baba 《Gastric cancer》2008,11(4):219-225
Background The muscularis propria of the stomach is histologically divided into three layers; namely, the innermost oblique, the inner
circular, and the outer longitudinal layers. In patients with gastric cancer the depth of tumor invasion has been reported
to correlate with lymph node metastasis and prognosis. However, it is unclear whether the depth of tumor invasion in the muscularis
propria has an effect on lymph node metastasis and prognosis.
Methods Fifty-nine gastric cancer patients with muscularis propria invasion were analyzed retrospectively. These patients were divided
into two groups, the inner group, with invasion up to the inner circular layer; and the outer group, with invasion beyond
the inner circular layer. The relationships between tumor invasion and clinicopathological factors and survival were evaluated.
Results Of the 59 patients, 34 were classified as the inner group, and 25 were classified as the outer group. The inner group had
a significantly lower probability of lymph node metastasis (P = 0.0053) and a significantly better overall cancer-specific survival (P = 0.017) than the outer group.
Conclusion Gastric cancers with muscularis propria invasion had heterogeneous prognoses according to the tumor depth in the muscularis
propria layers. 相似文献
993.
Dr. Koji Watanabe Chuzo Mori Noriyuki Haneda Makoto Inoue Kenji Kishida Yurika Hayashi Hiroshi Ozasa 《Pediatric cardiology》1991,12(1):52-53
Summary In an 18-year-old male with Eisenmenger syndrome cyanosis and erythrocytosis were increasing. The erythrocytosis diminished following oral bunazosin and phlebotomy was not needed during the treatment. When bunazosin was stopped, the erythrocytosis increased, but when it was resumed, the erythrocytosis and general fatigue diminished. 相似文献
994.
T Iwasaka K Hara Y Hayashi M Yokoyama T Hachisuga K Fukuda Y Okuma H Sugimori 《Gynecologic oncology》1991,42(1):39-43
We examined the antitumor effects of recombinant interferon-gamma (IFN-gamma) and tumor necrosis factor (TNF) on cervical adenocarcinoma cell lines, in vitro and in vivo. Four of five cell lines showed a high sensitivity to IFN-gamma, in vitro. One of five cell lines showed a remarkable sensitivity to TNF, in vitro. Only one cell line resistant to both IFN and TNF was derived from a well-differentiated adenocarcinoma of endocervical type. Experiments using nude mice bearing transplanted tumors revealed that these cytokines were also effective against tumors in vivo. All these observations suggest that IFN-gamma or TNF can have positive effects in the treatment of patients with adenocarcinoma of the uterine cervix. 相似文献
995.
Eighteen patients with advanced or recurrent carcinoma of the cervix were treated with a combination of peplomycin, vincristine, mitomycin-C, and cisplatin (POMP). Ten of the 16 evaluable patients (63%) responded, including 4 with a complete response. Median duration of the response was 7 months. Two of 6 with intrapelvic recurrent tumors responded to some extent following intraarterial infusion. The subcutaneous infusion of peplomycin was well accepted by the patients. Toxicity was tolerable. This regimen seemed to be one of the regimens which should be considered for the advanced or recurrent cervical cancer. 相似文献
996.
Epididymis Metastasis from Colon Carcinoma: A Case Report and a Review of the Japanese Literature 总被引:1,自引:0,他引:1
Kanno Keiichi; Ohwada Susumu; Nakamura Seiji; Ohya Toshihiro; lino Yuichi; Morishita Yasuo; Hayashi Masamichi; Yamanaka Hidetoshi; Fukusato Toshio; Koyama Tetsuya; Hikino Toshiaki 《Japanese journal of clinical oncology》1994,24(6):340-344
A 56-year-old Japanese man in whom a descending colon carcinomahad been resected underwent a high orchitectomy for metastaticepididymis from the colon. Metastatic carcinoma from the digestiveorgans to the spermatic cord (SC) and/or the intrascrotal contents(ISC) is rare. Fifty-four Japanese patients with metastasisfrom the digestive organs to the SC and/or the ISC were analyzed.The most frequent primary site was the stomach and the mostfrequent metastatic site was the spermatic cord. Our patientwas the first to exhibit metastasis from the colon to the epididymis.A primary site was identified in 24 patients subsequent to themetastatic tumor. Twenty patients had other organ metastatis.The prognosis for SC and/or ISC metastasis patients is poor.Our patients has survived for 18 months following his orchitectomywith no other organ metastasis (31 months after the primaryoperation). In our patient, monoclonal estrogen receptor stainingwas negative; however, further study must be undertaken. 相似文献
997.
S. Kawa M. Tokoo O. Hasebe K. Hayashi H. Imai H. Oguchi K. Kiyosawa S. Furuta T. Homma 《British journal of cancer》1994,70(3):481-486
A comparative study of a new tumour marker, CA242, and CA19-9 was conducted with special reference to their diagnostic usefulness in pancreatic cancer. CA242 showed sensitivity similar to that of CA19-9 for overall cases and early cases (stage I tumour) of pancreatic cancer. For other malignancies, the positive rates of CA242 were lower than those of CA19-9 except for colorectal cancer. An important characteristics of CA242 was that it was only slightly and infrequently elevated in the sera of patients with benign diseases such as chronic pancreatitis, chronic hepatitis and liver cirrhosis. This characteristic was more apparent in the patients with benign obstructive jaundice, indicating that the serum level of this marker was scarcely affected by cholestasis. Using cut-off levels corresponding to a 90% specificity, the clinical results obtained with CA242 in the diagnosis of pancreatic cancer were similar to those obtained with CA19-9, except that CA19-9 was falsely negative in some patients with early-stage pancreatic cancer. These findings suggest the usefulness of this marker for screening pancreatic cancer in patients on their first hospital visit. However, CA242 was found to be influenced by the Lewis blood group system. This unfavourable result is attributed to the C241 catcher antibody of this assay system, which has almost the same epitope specificity as the C50 and the NS19-9 monoclonal antibodies. In conclusion, CA242 is superior to CA19-9 in diagnosing pancreatic cancer by virtue of its higher specificity. 相似文献
998.
999.
Significance of Serum Neuron-specific Enolase as a Predictor of Relapse of Small Cell Lung Cancer 总被引:2,自引:0,他引:2
Nitta Takashi; Fukuoka Masahiro; Masuda Noriyuki; Kusunoki Yoko; Matsui Kaoru; Kudoh Shinzoh; Hirashima Tomonori; Yana Takashi; Itoh Kazunobu; Takada Minoru 《Japanese journal of clinical oncology》1995,25(5):179-183
We conducted a prospective study to evaluate the significanceof serum neuron-specific enolase (NSE) as a predictor of relapseof small cell lung cancer (SCLC). Patients entered into thestudy were drawn from those who had shown a complete or partialresponse to first-line chemotherapy with a concurrent declinein the NSE level to less than 10 ng/ml. When the serum NSE levelincreased to more than 15 ng/ml, the patient was restaged onthe basis of clinical, radiological, and bronchoscopic examinations.During the period from August 1988 to December 1990, 57 patientswith SCLC were enrolled and followed up until May 1992; Of thesepatients, 45 had clinical relapses, and 14 (31%) of them showeda clear elevation of the serum NSE level prior to the clinicalrecognition of relapse. Although one false-positive case wasnoted, this involved only a transient elevation of the NSE level.In patients who showed increased NSE levels, the relapses occurredin more difficult to detect silent sites such as the adrenalgland, liver, and deep lymph nodes. In addition, the percentageof patients demonstrating high NSE levels who were able to benefitfrom salvage chemotherapy was higher than for those who didnot (P<0.05). Our results indicate that serial NSE measurementsare useful for the early prediction of SCLC relapse and shouldhelp to facilitate early administration of salvage chemotherapyfor affected patients.(P<0.05) 相似文献
1000.
Relationship between the Pharmacokinetics of Irinotecan and Diarrhea during Combination Chemotherapy with Cisplatin 总被引:2,自引:0,他引:2
Shinzoh Kudoh Masahiro Fukuoka Noriyuki Masuda Atsuko Yoshikawa Yoko Kusunoki Kaoru Matsui Shun-ichi Negoro Nobuhide Takifuji Kazuhiko Nakagawa Tomonori Hirashima Takashi Yana Minoru Takada 《Cancer science》1995,86(4):406-413
Two phase I trials of irinotecan (CPT-11) in combination with cisplatin were conducted. In both cases, the dose-limiting toxicities were leukopenia and/or diarrhea. During these trials the pharmacokinetics of CPT-11 and its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), were investigated to evaluate the relationship between pharmacokinetic parameters and diarrhea, since this is an unpredictable and severe toxicity of combination chemotherapy using CPT-11 and cisplatin. Twenty-three previously untreated patients with advanced lung cancer were evaluated in the pharmacokinetic study. Ten patients received CPT-11 at 80 or 90 mg/m2 plus cisplatin at 60 mg/m2 . The other 13 patients received CPT-11 at 80 or 90 mg/m2 plus cisplatin at 80 mg/m2 with the granulocyte colony-stimulating factor support (2 μg/kg × 16 days). CPT-11 was given as a 90-min intravenous infusion on days 1, 8, and 15. Cisplatin was given on day 1. The pharmacokinetics of CPT-11 and SN-38 were analyzed on day 8 during the first course of treatment. The maximum tolerated dose of CPT-11 was 90 mg/m2 in both phase I trials. The severity of diarrhea was best correlated with the peak plasma concentration of SN-38 among the pharmacokinetic parameters tested. In addition, patients with a plasma SN-38 level > 12.4 ng/ml at 1.75 h after the start of CPT-11 infusion had a higher incidence of Eastern Cooperative Oncology Group grade 3–4 diarrhea than those with a lower SN-38 level ( P =0.0003). Stepwise logistic regression analysis identified the SN-38 concentration as a significant contributor to the development of diarrhea ( P =0.0021). We conclude that there is a clear relationship between the SN-38 concentration and diarrhea during chemotherapy with CPT-11 plus cisplatin. 相似文献